1-nitroascididemin | 155107-78-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-nitroascididemin
• 英文别名: 4-Nitro-2,12,15-triazapentacyclo[11.7.1.03,8.09,21.014,19]henicosa-1(21),2,4,6,8,10,12,14(19),15,17-decaen-20-one
• CAS: 155107-78-1
• 化学式: C₁₈H₈N₄O₃
• 分子量: 328.287
• InChiKey: GYNPAJQTGVMZOH-UHFFFAOYSA-N

物化性质

• 熔点：
  224 °C
• 沸点：
  666.1±50.0 °C(predicted)
• 密度：
  1.604±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  102
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-nitroascididemin 在 水 、 铁粉 、 溶剂黄146 作用下， 反应 1.0h， 以88%的产率得到4-amino-2,12,15-triazapentacyclo[11.7.1.03,8.09,21.014,19]henicosa-1(21),2,4,6,8,10,12,14(19),15,17-decaen-20-one
  参考文献：
  名称：

  Synthesis and In Vitro Antitumor Activity of Novel Ring D Analogues of the Marine Pyridoacridine Ascididemin: Structure−Activity Relationship

  摘要：

  Marine compounds with pyridoacridine skeletons are known to exhibit interesting antitumor activities. Ascididemin has already been reported as displaying significant antitumor activities in vitro and has also been found to have a relatively high global toxicity in vivo. We synthesized a series of 16 analogues (among which 11 compounds were different from previously described ones) with the aim of developing new anticancer agents with significant improved efficacy/tolerability ratios. These compounds were obtained either by total synthesis from 5,8-quinolinedione and substituted 2-aminoacetophenones or by the direct substitution of ascididemin. The different compounds and ascididemin used as the control compound were tested at six different concentrations on 12 different human cancer cell lines of various histopathological types (glioblastomas and breast, colon, lung, prostate, and bladder cancers). The IC50 value (ie., the drug concentration inhibiting the mean growth value of the 12 cell lines by 50%) of these compounds ranged over five log concentrations, i.e., between 10 000 and 0.1 nM. For several new chemical entities, the antitumor activity (determined in vitro) and tolerability (determined in vivo) were superior to those of the parent alkaloids, i.e., ascididemin and 2-bromoleptoclinidone.

  DOI：

  10.1021/jm0208774
• 作为产物：
  描述：

  ascididemin 在 硫酸 、 硝酸 作用下， 反应 2.0h， 以70%的产率得到1-nitroascididemin
  参考文献：
  名称：

  Synthesis and In Vitro Antitumor Activity of Novel Ring D Analogues of the Marine Pyridoacridine Ascididemin: Structure−Activity Relationship

  摘要：

  Marine compounds with pyridoacridine skeletons are known to exhibit interesting antitumor activities. Ascididemin has already been reported as displaying significant antitumor activities in vitro and has also been found to have a relatively high global toxicity in vivo. We synthesized a series of 16 analogues (among which 11 compounds were different from previously described ones) with the aim of developing new anticancer agents with significant improved efficacy/tolerability ratios. These compounds were obtained either by total synthesis from 5,8-quinolinedione and substituted 2-aminoacetophenones or by the direct substitution of ascididemin. The different compounds and ascididemin used as the control compound were tested at six different concentrations on 12 different human cancer cell lines of various histopathological types (glioblastomas and breast, colon, lung, prostate, and bladder cancers). The IC50 value (ie., the drug concentration inhibiting the mean growth value of the 12 cell lines by 50%) of these compounds ranged over five log concentrations, i.e., between 10 000 and 0.1 nM. For several new chemical entities, the antitumor activity (determined in vitro) and tolerability (determined in vivo) were superior to those of the parent alkaloids, i.e., ascididemin and 2-bromoleptoclinidone.

  DOI：

  10.1021/jm0208774

文献信息

• Biomimetic Synthesis of Ascididemin and Derivatives
  作者：Gari Gellerman、Amira Rudi、Yoel Kashman

  DOI：10.1055/s-1994-25446

  日期：——

  A two-step biomimetic synthesis of the pentacyclic pyrido[2,3,4-klacridine marine alkaloid ascididemin (3a) from quinolinequinone 5a and N-trifluoroacetamidokynuramine (4) is described. The crucial step (6 to 7) involves the simultaneous formation of two pyridine rings in a process which might well offer an explanation for the biogenetic synthesis in marine organisms. The preparation of substituted ascididemins by either starting from substituted quinoline-quinones, e.g., 5b to afford 11-methoxyascididemin (3b), or by nitration of 3a to the mono 1- or 3-nitroascididemins (8 and 9 respectively) is reported.

  本研究描述了一种五环吡啶并[2,3,4-klacridine]海洋生物碱 ascidemin（3a）的两步仿生物合成法，其原料是喹啉醌 5a 和 N-三氟乙酰胺基奎宁胺（4）。关键步骤（6 至 7）涉及两个吡啶环的同时形成，这一过程很可能为海洋生物的生物合成提供了解释。报告还介绍了从取代的喹啉醌（如 5b 生成 11-甲氧基蛔虫素（3b））开始，或通过硝化 3a 生成单 1-或 3-硝基蛔虫素（分别为 8 和 9）来制备取代的蛔虫素的方法。
• DERIVES D'ASCIDIDEMINE ET LEURS APPLICATIONS THERAPEUTIQUES
  申请人：LABORATOIRE L. LAFON

  公开号：EP1202992A2

  公开（公告）日：2002-05-08
• [EN] ASCIDIDEMIN DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS<br/>[FR] DERIVES D'ASCIDIDEMINE ET LEURS APPLICATIONS THERAPEUTIQUES
  申请人：LAFON LABOR

  公开号：WO2001012631A2

  公开（公告）日：2001-02-22

  La présente invention concerne une composition pharmaceutique comprenant une quantité efficace d'un composé choisi parmi les composés de formules (I) et (Ia), dans lesquelles, R1, R2, R3, R4, R5, R6 et R7 sont tels que définis à la revendication 1. Ces composés possèdent des propriétés cytotoxiques intéressantes conduisant à une application thérapeutique comme médicaments anti-tumoraux.
• Synthesis and In Vitro Antitumor Activity of Novel Ring D Analogues of the Marine Pyridoacridine Ascididemin: Structure−Activity Relationship
  作者：Evelyne Delfourne、Francis Darro、Philippe Portefaix、Chantal Galaup、Sylvie Bayssade、Anne Bouteillé、Laurent Le Corre、Jean Bastide、Françoise Collignon、Brigitte Lesur、Armand Frydman、Robert Kiss

  DOI：10.1021/jm0208774

  日期：2002.8.1

  Marine compounds with pyridoacridine skeletons are known to exhibit interesting antitumor activities. Ascididemin has already been reported as displaying significant antitumor activities in vitro and has also been found to have a relatively high global toxicity in vivo. We synthesized a series of 16 analogues (among which 11 compounds were different from previously described ones) with the aim of developing new anticancer agents with significant improved efficacy/tolerability ratios. These compounds were obtained either by total synthesis from 5,8-quinolinedione and substituted 2-aminoacetophenones or by the direct substitution of ascididemin. The different compounds and ascididemin used as the control compound were tested at six different concentrations on 12 different human cancer cell lines of various histopathological types (glioblastomas and breast, colon, lung, prostate, and bladder cancers). The IC50 value (ie., the drug concentration inhibiting the mean growth value of the 12 cell lines by 50%) of these compounds ranged over five log concentrations, i.e., between 10 000 and 0.1 nM. For several new chemical entities, the antitumor activity (determined in vitro) and tolerability (determined in vivo) were superior to those of the parent alkaloids, i.e., ascididemin and 2-bromoleptoclinidone.